- Dynavax Technologies (DVAX, Financial) revises stockholder value metrics to over $900 million and 62% return.
- Q1 2025 revenue jumps 34% YoY to $68.2 million, driven by HEPLISAV-B®'s 36% YoY revenue increase.
- 85% of $200 million share repurchase program completed; new vaccine programs announced.
Dynavax Technologies Corporation (DVAX) has issued a correction to its stockholder communication, revising its reported metrics for stockholder value generation. The company now states it has generated over $900 million in stockholder value, reflecting a 62% return when compared to the S&P Biotechnology Index. This is a correction from the previously stated figures of approximately $1 billion and a 104% return.
In its recent financial update, Dynavax reported a robust financial performance for Q1 2025, achieving a total revenue of $68.2 million, marking a 34% increase year-over-year. The company credited much of this growth to HEPLISAV-B®, its flagship hepatitis B vaccine, which reported $65 million in revenue, growing 36% year-over-year, and capturing approximately 43% of the U.S. market share.
Further reinforcing its strategic growth plans, Dynavax has successfully executed 85% of its $200 million share repurchase program, with $172 million completed by May 5, 2025. Additionally, Dynavax is expanding its vaccine pipeline, announcing new programs targeting pandemic influenza and Lyme disease, with clinical developments expected to commence in 2025 and 2027, respectively.
Despite these positive developments, Dynavax faces an ongoing proxy battle with Deep Track Capital, which challenges the company's strategic direction. In response, Dynavax urges stockholders to vote in favor of its board nominees to safeguard the company's long-term value creation strategy. Looking ahead, the company anticipates achieving an adjusted EBITDA of at least $75 million for 2025 and forecasts that its HEPLISAV-B® revenue will reach the upper half of its $305-325 million guidance range.
